Genmab A/S (OTCMKTS:GNMSF) Posts Quarterly Earnings Results

Genmab A/S (OTCMKTS:GNMSF) issued its quarterly earnings data on Thursday. The company reported $6.46 EPS for the quarter, Zacks reports. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%.

Genmab A/S Price Performance

Shares of GNMSF stock traded up $1.90 during trading hours on Thursday, hitting $285.00. The company had a trading volume of 60 shares, compared to its average volume of 2,316. The company’s fifty day moving average is $292.99 and its 200 day moving average is $241.30. Genmab A/S has a fifty-two week low of $170.00 and a fifty-two week high of $336.45. The stock has a market capitalization of $18.83 billion, a PE ratio of 14.31 and a beta of 0.95.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.